Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib.

Molecular cancer therapeutics·2026

Same author

Real-world mortality and the effect of comorbidities on survival in glioblastoma: A database study using computed phenotypes for rapid, reliable patient identification.

Neuro-oncology advances·2026

Same author

Adoptive cellular therapy prevents reconstitution of myeloid-derived suppressor cells in the glioma tumor microenvironment.

Neuro-oncology advances·2026

Same author

A Rare Presentation of Adult Primary Leptomeningeal Medulloblastoma: Case Report.

Case reports in pathology·2025

Same author

Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading.

Nature biomedical engineering·2025

Same author

Treatment Resistant Persister Cells Exploit Macrophage Lipid Metabolism to Sustain Glioblastoma Growth.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: May 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chasing cancer with chimeric antigen receptor therapy.

Christina D Pham¹, Duane A Mitchell

¹Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

|April 20, 2012

Summary

Genetically modified T cells with a chimeric antigen receptor (CAR) demonstrated significant tumor rejection activity. This approach led to complete regression of chronic lymphoid leukemia in a patient, advancing targeted cancer immunotherapy.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Related Experiment Videos

Last Updated: May 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Previous attempts using genetically modified T cells for cancer treatment faced significant challenges in human patients.
Adoptive lymphocyte therapy often encounters limitations in efficacy and patient application.

Purpose of the Study:

To evaluate the efficacy of genetically modified lymphocytes engineered with a chimeric antigen receptor (CAR) incorporating a costimulatory domain.
To assess the tumor rejection activity, expansion, and survival of these engineered T cells in a human patient.

Main Methods:

Genetically modified T cells were engineered to express a CAR with an integrated costimulatory domain.
These modified lymphocytes were transferred in vivo to a single patient with refractory chronic lymphoid leukemia.

Main Results:

The engineered T cells exhibited significantly enhanced tumor rejection activity.
Demonstrated significant expansion and prolonged survival of the modified lymphocytes post-transfer.
The patient achieved a complete regression of refractory chronic lymphoid leukemia.

Conclusions:

Chimeric antigen receptor (CAR) T cell therapy, incorporating costimulatory domains, offers a promising approach to overcome limitations in adoptive T cell therapy.
This strategy shows significant potential for developing specific and targeted immune-based cancer therapies.
Successful application in a patient with chronic lymphoid leukemia marks an encouraging advancement in cancer immunotherapy.